Our data indicate for the first time that MCL1 nuclear localization imbues sensitivity to Bcl-xL inhibitor A-1331852 in vitro and in vivo, phenocopying the impact of genetic ablation of MCL1 on the activity of A-1331852 in CRC cell lines. This evidence concerns the gene BCL2L1 and colorectal carcinoma.